Experience of prolonged use of dienogest in the treatment of endometriosis
- 作者: Olina A.A.1, Meteleva T.A.2
-
隶属关系:
- D.O. Ott Scientific Research Institute of Obstetrics, Gynecology and Reproduction
- Academician E.A. Wagner Perm State Medical University, Ministry of Health of Russia
- 期: 编号 7 (2018)
- 页面: 97-102
- 栏目: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248331
- DOI: https://doi.org/10.18565/aig.2018.7.97-102
- ID: 248331
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Background. Endometriosis is a chronic benign growth of endometrial-like tissues outside the uterine cavity. In the world, 6-10% of women of reproductive age are found, therefore, organ-preserving patience is the most preferred method of treatment. Progestins are the first-line drugs. Description. This article presents two clinical observations of patients with adenomyosis, long-term (over 6 years) use dienoguest (visanne) at a dose of 2 mg per day. Against the background of the drug, there is a marked improvement in health, a decrease in the level of pain syndrome, a decrease in the size of the uterus according to ultrasound. Conclusion. The presented clinical observations allow to recommend long-term therapy of adenomyosis with dienogest 2 mg (visanna drug), and confirm the high level of efficacy and safety of long-term therapy.
全文:
作者简介
Anna Olina
D.O. Ott Scientific Research Institute of Obstetrics, Gynecology and Reproduction
Email: olina29@mail.ru
MD, Deputy Director for Development
Tatyana Meteleva
Academician E.A. Wagner Perm State Medical University, Ministry of Health of RussiaAssistant of the Department of Obstetrics and Gynecology
参考
- Harris H.R., Chavarro J.E., Malspeis S., Willett W.C., Missmer S.A. Dairy-food, calcium, magnesium, and vitamin D. intake and endometriosis: a prospective cohort study. Am. J. Epidemiol. 2013; 177(5): 420-30.
- Эндометриоз: диагностика, лечение и реабилитация. Федеральные клинические рекомендации по ведению больных. М.: Российское общество акушеров-гинекологов; 2013. Available at: http://cr.rosminzdrav.ru
- Чернуха Г.Е. Современные прогестагены в лечении эндометриоза (обзор международных исследований). Проблемы репродукции. 2012; 4: 68-71.
- Hansen K.E., Kesmodel U.S., Baldursson E.B., Kold M., Forman A. Visceral syndrome in endometriosis patients. Eur. J. Gynecol. Reprod. Biol. 2014; 179: 198-203.
- Mansour G., Robinson R.D., Schenken R.S. Endometriosis and lipid concentration do we have to screen patients for hyperlipidemia? Obstet. Gynecol. 2015; 125(Suppl.1): 1S-44S, abstr. 349: Abstracts of the 63rd Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists. San Francisco, CA, May 2-6, 2015.
- Tani A., Yamamoto S., Maegawa M., Kunimi K., Matsui S., Keyama K. et al. Arterial stiffness is increased in young women with endometriosis. J. Obstet. Gynaecol. 2015; 35(7): 711-5.
- Culley L., Law C., Hudson N., Mitchell H., Denny E., Raine-Fenning N. A qualitative study of the impact of endometriosis on male partners. Hum. Reprod. 2017; 32(8): 1667-73.
- Hansen K.A. What is new in endometriosis? Best articles from the past year. Obstet. Gynecol. 2013; 121(5): 1104-6.
- Palmer S.S., Kurt B.T. Biomarkers in reproductive medicine: the promise, and can it be fulfilled? Fertil. Steril. 2013; 99(4): 954-62.
- Grandi G., Mueller M., Bersinger N.A., Cagnacci A., Volpe A., McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm. Res. 2016; 65(3): 183-92.
- Vercellini P., Buggio L., Berlanda N., Barbara G., Somigliana E., Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil. Steril. 2016; 106(7): 1552-71.
- Liang B., Wu L., Xu H., Cheung C.W., Fung W.Y., Wong S.W., Wang C.C. Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. Reprod. Biol. Endocrinol. 2018; 16(1): 32.
- Sugimoto K., Nagata C., Hayashi H., Yanagida S., Okamoto A. Use of dienogest over 53weeks for the treatment of endometriosis. J. Obstet. Gynaecol. Res. 2015; 41(12): 1921-6.
补充文件
